-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VNTLZO97vB9iJpSO7HpOmy5kmSm05GYqRPDm950JmO+p31+QSgTEKu8Q6vkkgF8T fqQggSjaqtbQxQjTpF2Uyw== 0001179110-06-005359.txt : 20060302 0001179110-06-005359.hdr.sgml : 20060302 20060302181504 ACCESSION NUMBER: 0001179110-06-005359 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060228 FILED AS OF DATE: 20060302 DATE AS OF CHANGE: 20060302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MALTAIS JO-ANN B CENTRAL INDEX KEY: 0001162528 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 06661248 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252494000 4 1 edgar.xml FORM 4 - X0202 4 2006-02-28 0 0000071478 LIPID SCIENCES INC/ LIPD 0001162528 MALTAIS JO-ANN B 7068 KOLL CENTER PARKWAY SUITE 401 PLEASANTON CA 94566-3111 0 1 0 0 VP, Scientific Affairs Stock Option (right to buy) 2.64 2006-02-28 4 A 0 5859 2.64 A 2016-02-27 Common Stock 5859 215000 D Vesting of the options will be subject to the condition of the occurrence of the treatment of the first patient in Lipid Sciences, Inc.'s contemplated clinical trial at Medstar Institute in Washington, D.C. and will be further subject to vesting over a three-year term in one-third increments beginning on the first anniversary of the grant date and on the second and third anniversary thereafter. By Sandra Gardiner, as Attorney-in-Fact on behalf of Jo-Ann B. Maltais, Vice President of Scientific Affairs 2006-03-02 -----END PRIVACY-ENHANCED MESSAGE-----